CD10-positive myxofibrosarcomas: a pitfall in the differential diagnosis of atypical fibroxanthoma.
J Cutan Pathol
; 37(7): 737-43, 2010 Jul.
Article
in En
| MEDLINE
| ID: mdl-20175824
ABSTRACT
CD10 is now commonly used to differentiate atypical fibroxanthoma (AFX) from melanoma, spindle cell and dedifferentiated variants of squamous cell carcinoma and leiomyosarcoma. However, we have encountered CD10-positive tumors that mimicked AFX but proved to be myxofibrosarcomas. The purpose of this study was to evaluate CD10 expression in a wide range of mesenchymal neoplasms that may involve the skin using tissue microarrays. Our results indicate that in addition to AFX, CD10 expression is common in myxofibrosarcomas, undifferentiated pleomorphic sarcomas, dermatofibromas and dermatofibrosarcoma protuberans. Myxofibrosarcomas commonly present in the skin and may be difficult to distinguish from AFX on small biopsies and CD10 positivity may confound the diagnostic difficulty.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Soft Tissue Neoplasms
/
Neprilysin
/
Histiocytoma, Benign Fibrous
/
Fibrosarcoma
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
J Cutan Pathol
Year:
2010
Document type:
Article
Affiliation country:
Estados Unidos
Publication country:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA